Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell and Follicular Lymphoma News

News
Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL
01/22/2024
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested...
01/22/2024
Oncology
News
Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy
01/19/2024
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that...
01/19/2024
Oncology

Recent News

News
Chemoimmunotherapy Demonstrates Real-World Long-Term Efficacy for Patients With Extensive-Stage Small Cell Lung Cancer
12/10/2024
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a...
12/10/2024
Oncology
News
Adjuvant PD-1/-L1 Inhibition Significantly Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma Regardless of PD-L1 Status
12/09/2024
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with...
12/09/2024
Oncology
Conference Coverage
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Myelofibrosis
12/07/2024
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to data presented at...
12/07/2024
Oncology
Conference Coverage
Novel JAK2 Inhibitor OB756 Treatment Well-Tolerated Among Patients With Myelofibrosis
12/07/2024
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a...
12/07/2024
Oncology
Conference Coverage
Bomedemstat Combined With Ruxolitinib Demonstrates Benefit Among Patients With Myelofibrosis
12/06/2024
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
According to results from a...
12/06/2024
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
Conference Coverage
Real-World Efficacy of Bispecific Antibodies for Patients With Relapsed or Refractory Large B-Cell Lymphomas
12/05/2024
According to results from a retrospective study presented at the 2024 ASH Annual Meeting & Exposition, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell...
According to results from a retrospective study presented at the 2024 ASH Annual Meeting & Exposition, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell...
According to results from a...
12/05/2024
Oncology
Conference Coverage
Second-Line Fedratinib Shows Promise for Patients With Myelofibrosis With Low Baseline Platelet Counts
12/05/2024
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
According to the phase 3...
12/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use